About this trial
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens.
In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2026 from 28-31 August 2026 in Munich, Germany.
The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.
Eligibility criteria
Qualifiers
All attendees including healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2026 from 28 to 31 August 2026
Subjects who declare that they are able to understand and give informed consent in English
Adult subjects (≥ 18 years of age)
Disqualifiers
Subjects not willing to provide his/her consent to participate in the study.
Subjects who are not suitable candidates for blood extraction.
Trial design
Treatments tested in this trial
- Capillary blood draw
- Questionnaire and Physical Exam
- Urine sample
- Questionnaire and Physical Exam